RECURRENT OR PERSISTENT OVARIAN CLEAR CELL CARCINOMA
Clinical trials for RECURRENT OR PERSISTENT OVARIAN CLEAR CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT OR PERSISTENT OVARIAN CLEAR CELL CARCINOMA trials appear
Sign up with your email to follow new studies for RECURRENT OR PERSISTENT OVARIAN CLEAR CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for recurrent ovarian and endometrial cancers? drug tazemetostat under study
Disease control OngoingThis phase II trial is testing the drug tazemetostat in 62 patients whose ovarian or endometrial cancer has returned after prior treatment. The goal is to see if tazemetostat can shrink tumors or stop them from growing. Participants will receive the drug and be monitored for resp…
Matched conditions: RECURRENT OR PERSISTENT OVARIAN CLEAR CELL CARCINOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New targeted drug shows promise for tough ovarian cancer
Disease control OngoingThis phase 2 trial tests a drug called CYH33 in 93 women with recurrent ovarian, fallopian tube, or peritoneal clear cell carcinoma that has a specific genetic change (PIK3CA mutation). The drug works by blocking a protein that helps cancer grow. The main goal is to see if it shr…
Matched conditions: RECURRENT OR PERSISTENT OVARIAN CLEAR CELL CARCINOMA
Phase: PHASE2 • Sponsor: Haihe Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC